Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
M. Marty(Hôpital Saint-Louis), V. Stahalova(Fakultní nemocnice Bulovka), Antonio Llombart‐Cussac(MedSIR (Spain)), Bernardo L. Rapoport(The Medical Oncology Centre of Rosebank), Marc Espié(Hôpital Saint-Louis), Alain Monnier(Maison des Sciences sociales et des Humanités - Lyon St-Étienne)
Cited by 197
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
|Annals of Oncology|2001|714
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
|Journal of Clinical Oncology|2008|464
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
|Journal of Clinical Oncology|2008|422